KODIAK SCIENCES ANNOUNCES FIRST TIME PRESENTATION OF PRIMARY ENDPOINT DATA FROM TARCOCIMAB TEDROMER PHASE 3 GLOW STUDY IN PATIENTS WITH DIABETIC RETINOPATHY AT AMERICAN ACADEMY OF OPHTHALMOLOGY ANNUAL MEETING ...Middle East

PALO ALTO, Calif., Nov. 1, 2023 /PRNewswire/ -- Kodiak Sciences Inc (NASDAQ: KOD) today announced that data from tarcocimab tedromer will be presented during the annual meeting of the American Academy of Ophthalmology (AAO) to be held November 3-6 in San Francisco. During the Retina...

Hence then, the article about kodiak sciences announces first time presentation of primary endpoint data from tarcocimab tedromer phase 3 glow study in patients with diabetic retinopathy at american academy of ophthalmology annual meeting was published today ( Thursday 02/11/2023 - 06:29 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( KODIAK SCIENCES ANNOUNCES FIRST TIME PRESENTATION OF PRIMARY ENDPOINT DATA FROM TARCOCIMAB TEDROMER PHASE 3 GLOW STUDY IN PATIENTS WITH DIABETIC RETINOPATHY AT AMERICAN ACADEMY OF OPHTHALMOLOGY ANNUAL MEETING )

Also on site :

• As Trump Bombs Iran, America’s Allies Watch Fitfully From Sidelines
• Israel And Hezbollah Exchange Fire As Middle East Conflict Widens
• British military base in Cyprus targeted in suspected drone attack